A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
Open Access
- 14 November 2006
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 95 (12) , 1637-1641
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Adjuvant Irinotecan Regimens in Combination with Infusional 5-Fluorouracil/Leucovorin Fail to Improve Outcomes in Surgically Resected Colorectal CancerClinical Colorectal Cancer, 2005
- Capecitabine as third line therapy in patients with advanced colorectal cancerActa Oncologica, 2005
- Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced MalignanciesClinical Cancer Research, 2004
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Phase II Study of Capecitabine in Patients With Fluorouracil-Resistant Metastatic Colorectal CarcinomaJournal of Clinical Oncology, 2004
- Phase II study of oral S‐1 for treatment of metastatic colorectal carcinomaCancer, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- α-Fluoro-β-alanine: Effects on the antitumor activity and toxicity of 5-fluorouracilBiochemical Pharmacology, 2000
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989